|Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma|
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
|Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study|
B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ...
Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998
|European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma …|
JM Foran, AZ Rohatiner, D Cunningham, RA Popescu, P Solal-Celigny, ...
Journal of Clinical Oncology 18 (2), 317-324, 2000
|Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts|
MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ...
Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003
|Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma|
J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ...
New England Journal of Medicine 372 (17), 1598-1607, 2015
|Clinical trials of antibody therapy|
MJ Glennie, PWM Johnson
Immunology today 21 (8), 403-410, 2000
|Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma|
P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ...
N Engl J Med 374, 2419-2429, 2016
|Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of …|
D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ...
The Lancet 381 (9880), 1817-1826, 2013
|Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ...
Annals of oncology 26, v116-v125, 2015
|Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.|
PW Johnson, AZ Rohatiner, JS Whelan, CG Price, S Love, J Lim, ...
Journal of Clinical Oncology 13 (1), 140-147, 1995
|Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection|
SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ...
Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010
|First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial|
A Hagenbeek, O Gadeberg, P Johnson, L Møller Pedersen, J Walewski, ...
Blood 111 (12), 5486-5495, 2008
|The mechanisms of action of rituximab in the elimination of tumor cells|
P Johnson, M Glennie
Seminars in oncology 30 (1), 3-8, 2003
|Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma|
SF Barrington, W Qian, EJ Somer, A Franceschetto, B Bagni, E Brun, ...
European journal of nuclear medicine and molecular imaging 37 (10), 1824-1833, 2010
|Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results|
ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
Blood 126 (6), 739-745, 2015
|Anti-CD20 monoclonal antibodies: historical and future perspectives|
SH Lim, SA Beers, RR French, PWM Johnson, MJ Glennie, MS Cragg
haematologica 95 (1), 135, 2010
|Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.|
AZ Rohatiner, PW Johnson, CG Price, SJ Arnott, JA Amess, AJ Norton, ...
Journal of Clinical Oncology 12 (6), 1177-1184, 1994
J Michels, PWM Johnson, G Packham
The international journal of biochemistry & cell biology 37 (2), 267-271, 2005
|Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the …|
AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ...
The Lancet Haematology 3 (5), e217-e227, 2016
|Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.|
FE Cotter, P Johnson, P Hall, C Pocock, N Al Mahdi, JK Cowell, G Morgan
Oncogene 9 (10), 3049-3055, 1994